Mepolizumab is under clinical development by GSK and currently in Phase III for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase III drugs for Chronic Obstructive Pulmonary Disease (COPD) have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Mepolizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mepolizumab overview
Mepolizumab (SB240563, Bosatria, Nucala, Xinkelai) is an anti-interleukin-5 (IL-5) recombinant humanized IgG1 monoclonal antibody. It is formulated as injectable solution and powder for solution for subcutaneous route of administration. Mepolizumab is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype and as an add-on treatment for severe refractory eosinophilic asthma in pediatric patients aged six up to 17 years, it is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
See Also:
It is under development for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilic chronic rhinosinusitis, nasal polyposis, chronic spontaneous urticaria, hypereosinophilic syndrome, bronchial asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD).
It was also under development for the treatment of severe atopic dermatitis and eosinophilic fasciitis.
GSK overview
GSK is a healthcare company that focuses on developing, manufacturing and commercializing general medicines, specialty medicines and vaccines. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.
For a complete picture of Mepolizumab’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
